Echo Therapeutics Presents Positive Clinical Trial Results of the Symphony tCGM System at the American Diabetes Association's 72nd Scientific Sessions
Echo Therapeutics, Inc. (Nasdaq: ECTE) presented an expanded analysis of data collected from subjects with either type 1 or type 2 diabetes during its recent clinical trial of its Symphony tCGM System. The data were presented during an oral presentation session on Friday, June 8 at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) in Philadelphia, PA.
The presentation [ADA abstract 007-OR], entitled "Transdermal Continuous Glucose Monitoring Following Skin Permeation," by Wayne Menzie, Echo's Director of Technology and Clinical Development, provided data from twenty (20) adult subjects with type 1 or type 2 diabetes whose glucose levels were monitored continuously for 24 hours.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.